RxDoctor Payments Data

Kaushal Shah, MD

Internal Medicine · Harriman, NYNPI 1659356715

Payments from drug & device makers

$767in general payments, 2019–2025

Across 30 payments — averaging $25.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$234
  • AstraZeneca$170
  • Boehringer Ingelheim$125
  • Pfizer$111
  • Exact Sciences$48
  • Novo Nordisk$34
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$76,257
Medicare patients
158
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$24,441
XareltoRivaroxaban11$9,213
Atorvastatin Calcium375$6,997
Incruse ElliptaUmeclidinium Bromide11$4,187
Losartan Potassium213$3,249
Tamsulosin Hcl80$1,901
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$1,501
Omeprazole83$1,427
Levothyroxine Sodium106$1,407
Rosuvastatin Calcium102$1,370
Venlafaxine Hcl ErVenlafaxine Hcl69$1,195
Dexlansoprazole DrDexlansoprazole11$1,100
Amlodipine Besylate145$965
Montelukast Sodium48$932
Famotidine29$914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$24,44119 claims
GSKIncruse Ellipta$234$4,18711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Harriman

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →